INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
The company's breast cancer screen test has also demonstrated superior accuracy over current tests.
Copyright 2024 – Finance News Network
Source: Finance News Network
27 Apr 2022 - Acorn Capital Investment Fund (ASX:ACQ) Portfolio Manager Rick Squire discusses key factors behind commodity demand and which commodities to keep an eye on.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More04 Nov 2019 - Altura Mining (ASX:AJM) Managing Director James Brown, talks about its rights issue to raise $21M, production at its Pilgangoora mine in the Pilbara and outlook for lithium demand.
Read More24 Jun 2020 - Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.
Read More19 Mar 2025 - Michael Fazzini, Sales and Distribution Executive at Capital Prudential, discusses the company's strategy.
Read More30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
Read More10 Oct 2023 - Cameron Perks - Principal Analyst - Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Read More16 Apr 2025 - Managing Director Jarrad Haynes shares how the firm is navigating risk, scaling development, and positioning for long-term growth.
Read More17 Feb 2023 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the company's upcoming plans to list on the NASDAQ and provides an update on the its clinical trials.
Read More10 May 2024 - Exploring tin's revival: Elementos CEO & MD Joe David discusses market trends and project developments.
Read More
